However the most active derivative , ticlopidine , was selected for further development .
At that time it was very uncommon to screen for new antiplatelet agents , as the connection between platelet aggregation , thrombosis and cardiovascular incidents was disputed .
The most active derivative , ticlopidine , was selected for further development .
At that time it was very uncommon to screen for new antiplatelet agents , as the connection between platelet aggregation , thrombosis and cardiovascular incidents was disputed .